Sub-Study of Cambria-1 & Cambria-2

A Multicentre, Open-Label Study Assessing Ophthalmic Safety of Camizestrant in ER+/HER2- Early Breast Cancer Patients Either Initiating Adjuvant Endocrine-Based Therapy (CAMBRIA-2) or Having Been Treated with Standard Adjuvant Endocrine-Based Therapy for At Least 2 Years (CAMBRIA-1)

Objective

Clinical Trial Details

IRB Protocol Number

2025.017

Principal Investigator(s)

Jason Jones, MD

Clinical Trial Categories

• Cancer
• Breast Cancer

Contact

Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org